Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06817122 · ClinicalTrials.gov registry record · NA

The "Let's Talk Tech" Tool to Support Decision Making About Technology Use

A NA study of Mild Cognitive Impairment (MCI) and Dementia, Mild, sponsored by University of Washington.

Recruiting
Registry status
NA
Development phase
240
Enrollment target
1
Study location

NCT06817122: Recruiting NA study of Mild Cognitive Impairment (MCI) and Dementia, Mild, sponsored by University of Washington.

NCT06817122 is a NA study of Mild Cognitive Impairment (MCI) and Dementia, Mild that is actively recruiting participants, run by University of Washington. The registered enrollment target is 240 participants, above the 147-participant average among 19 other Mild Cognitive Impairment (MCI) trials with a reported enrollment target (63% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06817122, a NA study of Mild Cognitive Impairment (MCI) and Dementia, Mild, is actively recruiting participants, sponsored by University of Washington.

RECRUITING
Registry status
NA
Development phase
240 participants
Enrollment target
1
Study location

Study Summary

The goal of this research is to educate people about different technologies to support care at home when someone is experiencing memory difficulties. "Let's Talk Tech" is a new tool to educate people about technologies commonly used to support care and monitor safety, and help families talk about their feelings about them to understand each other's perspectives. The goal of this clinical trial is to learn if "Let's Talk Tech" helps people feel more prepared to make decisions about technologies. Researchers will compare Let's Talk Tech to usual care (no intervention) to see if Let's Talk Tech increases peoples' preparedness and confidence to make decisions about technologies. Participants will: * Use the Let's Talk Tech web application together with their study partner that takes up to an hour or do nothing. * Complete three surveys. The second survey will be taken within 2 weeks of the first and the last survey will be taken 3 months after the first.

Primary Outcome

This is one of the three primary outcomes that are not mechanisms of change variables. Participant rates on a 5-point Likert scale \[1="Strongly agree" to 5="Strongly disagree"\] how much they agree with the statement that they feel prepared to make decisions about technology use for their study partner.

Conditions Studied

Mild Cognitive Impairment (MCI) Dementia, Mild

Interventions

  • BEHAVIORAL Let's Talk Tech

Study Locations (1)

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2025-02-07
Est. Completion 2026-04
Phase NA
University of Washington

1,048 total trials

What NCT06817122 shows while recruiting

NCT06817122 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 147-participant average among 19 other Mild Cognitive Impairment (MCI) trials with a reported enrollment target (63% higher).

The record links to 2 conditions, with Mild Cognitive Impairment (MCI) appearing as the primary indexed condition, and to 1 intervention - of which Let's Talk Tech is the first listed.

NCT06817122 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT06817122 about?

NCT06817122 is a clinical study titled "The "Let's Talk Tech" Tool to Support Decision Making About Technology Use". The goal of this research is to educate people about different technologies to support care at home when someone is experiencing memory difficulties. "Let's Talk Tech" is a new tool to educate people about technologies commonly used to support care and monitor safety, and help families talk about th...

What is the current status of trial NCT06817122?

This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2025-02-07. Estimated completion is 2026-04.

What conditions does trial NCT06817122 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment (MCI), Dementia, Mild.

What interventions are being tested in trial NCT06817122?

The interventions under investigation include: Let's Talk Tech (BEHAVIORAL).

Who is sponsoring clinical trial NCT06817122?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06817122 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mild Cognitive Impairment (MCI)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06817122's enrollment target sits among peer trials

240 3rd of 19 higher than 16 of 19 other Mild Cognitive Impairment (MCI) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mild Cognitive Impairment (MCI) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02855554 · 240 participants · NA

    Quantitative Cardiac Parametric Mapping

  • NCT03230565 · 240 participants · Phase 4

    Continuous Infusions vs Scheduled Bolus Infusions

  • NCT03399929 · 240 participants

    Traumatic Brain Injury and Stroke Long Term Outcome

  • NCT03583710 · 240 participants · Phase 3

    Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06817122

Source: ClinicalTrials.gov NCT06817122, the US trial registry maintained by the National Library of Medicine. NCT06817122 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.